CN109485704B - Expression system of meningococcal fHbp protein - Google Patents
Expression system of meningococcal fHbp protein Download PDFInfo
- Publication number
- CN109485704B CN109485704B CN201811425674.0A CN201811425674A CN109485704B CN 109485704 B CN109485704 B CN 109485704B CN 201811425674 A CN201811425674 A CN 201811425674A CN 109485704 B CN109485704 B CN 109485704B
- Authority
- CN
- China
- Prior art keywords
- fhbp
- promoter
- expression system
- protein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101710186862 Factor H binding protein Proteins 0.000 title claims abstract description 65
- 230000014509 gene expression Effects 0.000 title claims abstract description 38
- 239000013598 vector Substances 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 101150103518 bar gene Proteins 0.000 claims description 22
- 239000003550 marker Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 235000019219 chocolate Nutrition 0.000 claims description 4
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000007400 DNA extraction Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 33
- 241000589158 Agrobacterium Species 0.000 abstract description 15
- 241000219195 Arabidopsis thaliana Species 0.000 abstract description 9
- 239000013604 expression vector Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 2
- 108700010070 Codon Usage Proteins 0.000 abstract 2
- 244000046052 Phaseolus vulgaris Species 0.000 abstract 1
- 229940126578 oral vaccine Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 241000219194 Arabidopsis Species 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid Chemical compound CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000005561 Glufosinate Substances 0.000 description 1
- 241000231392 Gymnosiphon Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108020005120 Plant DNA Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8222—Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明属于基因工程技术领域,具体涉及一种脑膜炎球菌fHbp蛋白的表达系统。The invention belongs to the technical field of genetic engineering, in particular to an expression system of meningococcal fHbp protein.
背景技术Background technique
脑膜炎球菌疾病因高发病率和高死亡率使其成为一个严峻的全球公共卫生问题。全世界几乎每年有50多万侵扰性脑膜炎疾病的病例,其中有6万的病人留下了严重的后遗症。在发展中国家2%的出生儿童5岁前死于脑膜炎。人类几乎所有的脑膜炎球菌病例是由A、B、C、W135和Y血清型引起的。Sanofi-Pasteur研制的A、C、W135和Y的四价荚膜多糖疫苗证明能有效预防这四种血清型。B群的荚膜多糖与人少数成熟组织神经细胞黏附分子同源。因此不能引起免疫。但是,Novartis利用“反向疫苗学”研制的含有4种外膜蛋白抗原的能预防脑膜炎球菌B群的疫苗已经进入III期临床,并且其中证明fHbp的免疫原性优于其他外膜蛋白。目前fHbp的基因工程化疫苗仍由原核表达系统表达。但其中高昂成本和产品中易含有热源的问题无法满足社会的需要,亟需一种全新的表达系统。Meningococcal disease is a serious global public health problem due to its high morbidity and mortality. Almost every year there are more than 500,000 cases of invasive meningitis disease worldwide, of which 60,000 suffer from severe sequelae. 2% of children born in developing countries die of meningitis before the age of 5. Almost all meningococcal cases in humans are caused by serotypes A, B, C, W135 and Y. The tetravalent capsular polysaccharide vaccine developed by Sanofi-Pasteur for A, C, W135 and Y proved to be effective against these four serotypes. The capsular polysaccharide of group B is homologous to the neuronal cell adhesion molecule in a few mature tissues of humans. Therefore, immunity cannot be induced. However, a vaccine developed by Novartis using "reverse vaccinology" containing four outer membrane protein antigens to prevent meningococcal group B has entered Phase III clinical trials, and it has been proved that the immunogenicity of fHbp is better than other outer membrane proteins. At present, the genetically engineered vaccine of fHbp is still expressed by prokaryotic expression system. However, the high cost and the problem of easily containing heat sources in the products cannot meet the needs of society, and a new expression system is urgently needed.
植物生物反应器的兴起,使低成本规模化生产基因工程疫苗,简化后期纯化工艺,以及产品不含热源方面体现出极大的技术优势,具有广阔的应用前景。The rise of plant bioreactors has shown great technical advantages in low-cost large-scale production of genetically engineered vaccines, simplified post-purification processes, and products that do not contain pyrogens, and have broad application prospects.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种脑膜炎球菌fHbp蛋白的表达系统。The purpose of the present invention is to provide an expression system of meningococcal fHbp protein.
本发明具体通过以下技术方案实现:The present invention is specifically realized through the following technical solutions:
一种脑膜炎球菌fHbp蛋白的表达系统,所述的表达系统包含fHbp抗原基因和载体pCAMBIA1301,所述的表达系统为pCAMBIA-fHbp。An expression system of meningococcal fHbp protein, said expression system comprising fHbp antigen gene and carrier pCAMBIA1301, said expression system is pCAMBIA-fHbp.
所述的表达系统中包含能使fHbp抗原基因在植物中高效表达的启动子,所述的启动子为β-phaseolin启动子。The expression system includes a promoter capable of efficiently expressing the fHbp antigen gene in plants, and the promoter is a β-phaseolin promoter.
所述的β-phaseolin启动子的核苷酸序列如SEQ ID NO.1所示。The nucleotide sequence of the β-phaseolin promoter is shown in SEQ ID NO.1.
所述的表达系统中包括筛选标记,所述的筛选标记为Bar基因。The expression system includes a selectable marker, and the selectable marker is Bar gene.
本发明上述β-phaseolin启动子在提高fHbp抗原基因在植物中高效表达中的应用也在本发明的保护范围之内。The application of the above-mentioned β-phaseolin promoter of the present invention in improving the high-efficiency expression of the fHbp antigen gene in plants also falls within the protection scope of the present invention.
所述的Bar基因在筛选表达系统pCAMBIA-fHbp中的应用也在本发明的保护范围之内。The application of the described Bar gene in screening the expression system pCAMBIA-fHbp also falls within the protection scope of the present invention.
另一方法,本发明还提供了制备上述表达系统的方法,具体包括以下内容:将本发明的包含fHbp的抗原蛋白基因,亚克隆入能使该基因高效表达的载体中,将能提高表达量的种子特异启动子,以及能筛选出转化植株的筛选标记的基因引入该表达系统中。Another method, the present invention also provides a method for preparing the above-mentioned expression system, which specifically includes the following content: subcloning the antigenic protein gene comprising fHbp of the present invention into a vector that can efficiently express the gene, which will increase the expression level. The seed-specific promoter of , and a gene that can screen out transformed plants are introduced into the expression system.
所述的表达系统引入的启动子为β-phaseolin启动子,所述的筛选标记为Bar基因,所述的载体为pCAMBIA1301。The promoter introduced by the expression system is β-phaseolin promoter, the selection marker is Bar gene, and the vector is pCAMBIA1301.
在本发明的一个具体实施例中,可通过农杆菌感染法将上述构建体的fHbp基因的表达框和Bar基因表达框随机整合入植物基因组中,使植物能生产fHbp抗原蛋白。In a specific embodiment of the present invention, the expression cassette of the fHbp gene and the expression cassette of the Bar gene of the above construct can be randomly integrated into the plant genome by the Agrobacterium infection method, so that the plant can produce the fHbp antigen protein.
在本发明的一个具体实施例中,设计Bar基因特异性引物对通过除草剂筛选呈阳性的植株进行PCR检测,去除掉PCR检测为阴性但抗除草剂的“假阳性”植株。In a specific embodiment of the present invention, Bar gene-specific primers are designed to perform PCR detection on plants that are positive for herbicide screening, and "false positive" plants that are negative in PCR detection but resistant to herbicides are removed.
优选的,对Bar基因PCR检测筛选出的“Bar基因阳性植株”进行fHbp目的基因的PCR检测。去除转化过程中只有Bar基因整合入植物基因组而fHbp未整合入植物基因组的植物。通过两轮的PCR检测,确定了所有筛选出的拟南芥均含有fHbp目的基因和Bar筛选标记基因。Preferably, PCR detection of the target gene of fHbp is performed on the "Bar gene positive plants" screened by PCR detection of Bar gene. Plants in which only the Bar gene was integrated into the plant genome and the fHbp was not integrated into the plant genome during the transformation were removed. Through two rounds of PCR detection, it was confirmed that all the screened Arabidopsis thaliana contained the fHbp target gene and the Bar selection marker gene.
由于目前没有市售的fHbp抗体用于检测fHbp蛋白的表达量,但是,农杆菌的整合机制是把含有目的基因和筛选标记表达框的T-DNA区整合到植物基因组中。因此,在本发明中,通过检测筛选标记Bar基因表达量来间接确定目的基因fHbp基因的表达量。本发明中通过PCR筛选出的植物通过Bar基因胶体金试纸条检测Bar基因的表达量。将样品的浓度稀释10倍,进行试纸条检测,结果仍为阳性的,确定为Bar基因高表达的拟南芥,间接证明目的基因fHbp的高表达。Since there is currently no commercially available fHbp antibody for detecting the expression level of fHbp protein, the integration mechanism of Agrobacterium is to integrate the T-DNA region containing the target gene and the expression cassette of the selection marker into the plant genome. Therefore, in the present invention, the expression level of the target gene fHbp gene is indirectly determined by detecting the expression level of the screening marker Bar gene. In the plants screened by PCR in the present invention, the expression level of the Bar gene is detected by the Bar gene colloidal gold test strip. The concentration of the sample was diluted 10 times, and the test strip was tested. The result was still positive, which was determined to be Arabidopsis thaliana with high Bar gene expression, which indirectly proved the high expression of the target gene fHbp.
农杆菌介导的外源基因整合是多位点和随机整合,植物在遗传时遗传因子会发生分离,由于外源基因在植物中不是单拷贝,这样外源基因不会随基因组稳定的遗传。本发明通过Southern-Blot检测外源基因的拷贝,来筛选出能稳定遗传的高表达植株。The integration of foreign genes mediated by Agrobacterium is multi-site and random integration, and the genetic factors will be separated when plants are inherited. Since the foreign genes are not single copies in plants, the foreign genes will not be stably inherited with the genome. In the present invention, the copy of the exogenous gene is detected by Southern-Blot to screen out the high-expression plants that can stably inherit.
本发明的有益效果为:The beneficial effects of the present invention are:
本发明首先在表达载体上有了突破,以种子特异启动子替换掉组成型启动子,使蛋白特异的在种子中表达提高了蛋白的表达量。农杆菌介导的拟南芥侵染方法是独有的技术平台。这在降低生产成本、简化生产工艺和提高产品的安全性等诸多方面体现出极大的优势。The invention first makes a breakthrough in the expression vector, replacing the constitutive promoter with the seed-specific promoter, so that the protein is specifically expressed in the seed and the expression amount of the protein is increased. The Agrobacterium-mediated Arabidopsis infection method is a unique technology platform. This shows great advantages in many aspects, such as reducing production costs, simplifying production processes and improving product safety.
附图说明Description of drawings
图1是表达载体p1301-phas-fHbp酶切鉴定;Fig. 1 is the restriction enzyme digestion identification of expression vector p1301-phas-fHbp;
图2是转化拟南芥Bar基因PCR检测结果:M:DL100DNAmarker(Trans Gen);阳:p1301-phas-fHbp;WT:未转化的拟南芥基因组DNA;1-21:转化的拟南芥;Figure 2 shows the PCR detection results of the transformed Arabidopsis Bar gene: M: DL100 DNA marker (Trans Gen); M: p1301-phas-fHbp; WT: untransformed Arabidopsis genomic DNA; 1-21: transformed Arabidopsis;
图3是转化拟南芥fHbp的PCR检测结果;M:DL2000DNAmarker(TAKARA);阳:p1301-phas-fHbp;WT:未转化的拟南芥基因组DNA;1-23:转化的拟南芥;Figure 3 is the PCR detection result of transformed Arabidopsis fHbp; M: DL2000 DNA marker (TAKARA); P: p1301-phas-fHbp; WT: untransformed Arabidopsis genomic DNA; 1-23: transformed Arabidopsis;
图4是试纸条检测Bar基因表达量的结果;左:Bar试纸条检测结果;右:稀释10倍后Bar试纸条检测结果;Figure 4 is the result of the test strip detecting Bar gene expression; Left: Bar test strip detection result; Right: Bar test strip detection result after diluting 10 times;
图5是目的蛋白fHbp的SDS-PAGE电泳结果;M:protein low marker(TAKARA);WT:未转化的拟南芥;1-8:转化的拟南芥;Figure 5 is the result of SDS-PAGE electrophoresis of the target protein fHbp; M: protein low marker (TAKARA); WT: untransformed Arabidopsis; 1-8: transformed Arabidopsis;
图6是目的蛋白fHbp高表达植株的Southern-Blot检测结果;M:Trans 15KDNAmarker;+:p1301-phas-fHbp;-:未转化的拟南芥;01-06:fHbp高表达植株;Figure 6 shows the results of Southern-Blot detection of plants with high expression of target protein fHbp; M: Trans 15K DNA marker; +: p1301-phas-fHbp; -: untransformed Arabidopsis; 01-06: plants with high fHbp expression;
图7是fHbp高表达植株纯化后SDS-PAGE检测结果;M:Protein Molecular WeightMarker(Low);1:未转化的拟南芥总蛋白;2:转化的拟南芥总蛋白;3:纯化后的fHbp蛋白;Figure 7 shows the results of SDS-PAGE after purification of fHbp high-expressing plants; M: Protein Molecular WeightMarker (Low); 1: untransformed Arabidopsis total protein; 2: transformed Arabidopsis total protein; 3: purified fHbp protein;
图8是ELISA检测血清IgG的滴度:对照组为PBS缓冲溶液;实验组为fHbp/弗氏佐剂制备物。Figure 8 is the titer of serum IgG detected by ELISA: the control group is PBS buffer solution; the experimental group is fHbp/Freund's adjuvant preparation.
具体实施方式Detailed ways
下面将结合本发明具体的实施例,对本发明技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions of the present invention will be clearly and completely described below with reference to specific embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.
实施例1 fHbp抗原基因的克隆与植物表达载体的构建Example 1 Cloning of fHbp antigen gene and construction of plant expression vector
将MenB标准株MC58划于巧克力固体培养基上。37℃,5%CO2培养36-48hr。挑取直径1.0-1.5mm的单菌落用PBS重悬,利用Universal Genomic DNA Extraction Kit提取MC58全基因组。根据已知的fHbp序列利用Primer Premier5.0设计fHbp上游和下游两条特异性引物并在5'和3'引入了NcoI和HindIII酶切位点,引物序列分别为:The MenB standard strain MC58 was streaked on chocolate solid medium. Incubate for 36-48hr at 37°C, 5% CO2 . A single colony with a diameter of 1.0-1.5 mm was picked and resuspended in PBS, and the whole genome of MC58 was extracted using Universal Genomic DNA Extraction Kit. According to the known fHbp sequence, Primer Premier5.0 was used to design two specific primers upstream and downstream of fHbp and introduced NcoI and HindIII restriction sites at the 5' and 3'. The primer sequences are:
上游引物:5'ATCGTCCATGGGACATCATCATCATCATC 3';Upstream primer: 5'ATCGT CCATGG GACATCATCATCATCATC 3';
下游引物:5'AAGCTTAATTAGCCATAGAAATAGCAGC 3'。Downstream primer: 5' AAGCTT AATTAGCCATAGAAATAGCAGC 3'.
扩增出fHbp片段并连入pEASY-T1中。载体命名为pEASY-T1-fHbp。The fHbp fragment was amplified and ligated into pEASY-T1. The vector was named pEASY-T1-fHbp.
通过Nco I和Hind III酶分别消化pEASY-T1-fHbp和p1301-phas,1%的琼脂糖凝胶电泳检测酶切效果,并分别回收pUC57-fHbp的小片段和p1301-phas的大片段。回收的产物用T4 DNA ligase 16℃过夜连接。连接产物转化大肠杆菌,接种在含有氨苄青霉素(100μg/mL)的LB固体培养基上。在固体培养基上挑取抗性单克隆菌落进行菌液PCR和Nco I和Hind III酶切鉴定。酶切结果如图1所示。The pEASY-T1-fHbp and p1301-phas were digested by Nco I and Hind III enzymes, respectively, and the digestion effect was detected by 1% agarose gel electrophoresis, and the small fragment of pUC57-fHbp and the large fragment of p1301-phas were recovered respectively. The recovered product was ligated with T4 DNA ligase at 16 °C overnight. The ligation product was transformed into E. coli and plated on LB solid medium containing ampicillin (100 μg/mL). The resistant monoclonal colonies were picked on solid medium for PCR and identification by Nco I and Hind III digestion. The digestion results are shown in Figure 1.
PCR反应体系:PCR reaction system:
酶切反应体系:Enzyme cleavage reaction system:
连接反应体系:Ligation reaction system:
实施例2植物表达载体转化农杆菌Example 2 Transformation of Agrobacterium with plant expression vector
1)农杆菌EHA105感受态细胞的制备1) Preparation of Agrobacterium EHA105 competent cells
接种农杆菌EHA105单菌落于5mLYEP液体培养基中,28℃220rpm培养过夜。取2mL过夜培养菌液转入50mLYEP液体培养基中,28℃220rpm培养至OD600为0.5左右,冰浴30min,4℃5000rpm离心5min,弃上清,加入700μL 50mmol/L的CaCl2和300μL 80%甘油重悬菌体,每管100μL分装,-80℃保存。A single colony of Agrobacterium EHA105 was inoculated into 5 mL YEP liquid medium, and cultured overnight at 28°C and 220 rpm.
2)转化农杆菌2) Transform Agrobacterium
取20ng纯化的质粒pCAMBIA-fHbp,加入到100μL农杆菌感受态中,混匀,冰浴30min,转入液氮5min,迅速置于37℃温育5min,加入800μL YEP液体培养基,28℃220rpm培养4-5h。将菌液转移至含有50mg/L的卡那霉素固体YEP培养基中,涂布于整个平板,28℃培养1-2天。Take 20ng of purified plasmid pCAMBIA-fHbp, add it to 100μL of Agrobacterium competent, mix well, ice bath for 30min, transfer to liquid nitrogen for 5min, quickly incubate at 37°C for 5min, add 800μL YEP liquid medium, 28°C 220rpm Incubate for 4-5h. The bacterial liquid was transferred to solid YEP medium containing 50 mg/L kanamycin, spread on the entire plate, and cultured at 28°C for 1-2 days.
3)转化农杆菌的筛选鉴定3) Screening and identification of transformed Agrobacterium
筛选抗性菌落于5mL含有50mg/L卡那霉素的YEP液体培养基中,28℃220rpm培养1天,离心,提取质粒,酶切电泳检测片段大小。The resistant colonies were screened in 5 mL of YEP liquid medium containing 50 mg/L kanamycin, cultured at 28°C and 220 rpm for 1 day, centrifuged, and the plasmid was extracted, and the size of the fragment was detected by enzyme digestion and electrophoresis.
实施例3农杆菌介导的转化及转化植株除草剂抗性的筛选Example 3 Agrobacterium-mediated transformation and screening of transformed plants for herbicide resistance
1)农杆菌工程菌的制备1) Preparation of Agrobacterium engineering bacteria
取带有表达载体的农杆菌菌种,菌种与培养基1:200的比例加入到含有50mg/L卡那霉素和含有25mg/L利福平霉素的YEP液体培养基中,28℃220rpm培养至OD600为0.5-0.6,5000rpm离心5min收集菌体。将收集的菌体重悬于侵染液中,调至OD600为1.0-1.2,备用。Take the Agrobacterium strain with the expression vector, and add it to the YEP liquid medium containing 50 mg/L kanamycin and 25 mg/L rifampicin at a ratio of 1:200 to the medium at 28°C. Cultivated at 220 rpm until OD 600 was 0.5-0.6, and centrifuged at 5000 rpm for 5 min to collect bacterial cells. The collected bacteria were resuspended in the infection solution, adjusted to OD 600 of 1.0-1.2, and used for later use.
2)拟南芥的转化2) Transformation of Arabidopsis
A.将已抽薹含有花蕾的拟南芥整株浸泡在农杆菌菌液中,浸染5min,取出拟南芥,放置于暗处24h;A. Soak the whole plant of Arabidopsis thaliana that has been bolted and contain flower buds in Agrobacterium solution for 5 minutes, take out the Arabidopsis thaliana, and place it in the dark for 24 hours;
B.侵染后的植株待2-3周后,采集黄色的种荚;B. After 2-3 weeks of infection, collect yellow seed pods;
C.将采集的种子均匀播种到花盆中,待长出两片真叶时,喷洒1%的草铵磷筛选,共喷洒3次,每次间隔5天。C. Evenly sow the collected seeds into flowerpots, when two true leaves grow,
实施例4转化植株的分子生物学检测Example 4 Molecular biological detection of transformed plants
1)转化植株的fHbp基因和Bar基因的PCR检测1) PCR detection of fHbp gene and Bar gene of transformed plants
取0.05g拟南芥叶片在液氮中研碎,加入1mL CTAB提取缓冲液(75mM 1M Tris-HCl(pH8.0),100mM 0.5M EDTA(pH8.0),1.05M NaCl,0.75%40K PVP,加水定容至1L),65℃孵育30min,12000rpm离心10min,将上清液转入新离心管中,加入等体积的酚/氯仿/异戊醇(体积比25:24:1)充分混匀,12000rpm离心10min。将上清转入新离心管中,加入等体积的氯仿充分混匀,12000rpm离心10min。将上清转入新离心管中,加入二倍体积无水乙醇,-20℃沉淀DNA。30min后12000rpm离心10min,弃去上清,干燥沉淀,加入ddH2O回溶备用。以抗性植株总DNA为模板,为转化的拟南芥总DNA做阴性对照,以pUC57-fHbp质粒做阳性对照,根据fHbp设计特异性引物,两条引物分别为:Take 0.05g Arabidopsis leaves and grind them in liquid nitrogen, add 1mL CTAB extraction buffer (75mM 1M Tris-HCl (pH8.0), 100mM 0.5M EDTA (pH8.0), 1.05M NaCl, 0.75% 40K PVP, Add water to volume to 1L), incubate at 65°C for 30min, centrifuge at 12000rpm for 10min, transfer the supernatant to a new centrifuge tube, add an equal volume of phenol/chloroform/isoamyl alcohol (volume ratio 25:24:1) and mix well , 12000rpm centrifugation for 10min. The supernatant was transferred to a new centrifuge tube, an equal volume of chloroform was added to mix well, and centrifugation was performed at 12,000 rpm for 10 min. Transfer the supernatant to a new centrifuge tube, add twice the volume of absolute ethanol, and precipitate DNA at -20°C. After 30 minutes, centrifuge at 12,000 rpm for 10 minutes, discard the supernatant, dry the precipitate, and add ddH 2 O to redissolve for later use. Using the total DNA of the resistant plants as a template, the total DNA of the transformed Arabidopsis thaliana was used as a negative control, and the pUC57-fHbp plasmid was used as a positive control, and specific primers were designed according to fHbp. The two primers are:
上游引物:5'ATCGTCCATGGGACATCATCATCATCAT 3';Upstream primer: 5'ATCGTCCATGGGACATCATCATCATCAT 3';
下游引物:5'AAGCTTAATTAGCCATAGAAATAGCAG 3'。Downstream primer: 5'AAGCTTAATTAGCCATAGAAATAGCAG 3'.
根据Bar基因设计特异性引物,两条引物分别为:Specific primers are designed according to the Bar gene, and the two primers are:
上游引物:5'TCAAATCTCGGTGACGGGCAGGA 3';Upstream primer: 5'TCAAATCTCGGTGACGGGCAGGA 3';
下游引物:5'ATGAGCCCAGAACGACGCCCGGC 3'。Downstream primer: 5'ATGAGCCCAGAACGACGCCCGGC 3'.
扩增产物用1%的琼脂糖凝胶电泳检测。扩增fHbp基因反应程序:95℃预变性5min;95℃变性30s;56℃退火30s;72℃延伸1min20s;30个循环;72℃后延伸7min;4℃终止反应。检测结果如图2。Amplification products were detected by 1% agarose gel electrophoresis. Amplification of fHbp gene reaction program: pre-denaturation at 95°C for 5min; denaturation at 95°C for 30s; annealing at 56°C for 30s; extension at 72°C for 1min20s; 30 cycles; extension at 72°C for 7min; termination of the reaction at 4°C. The test results are shown in Figure 2.
PCR反应体系:PCR reaction system:
Bar基因PCR反应程序:95℃预变性5min;95℃变性30s;56℃退火30s;72℃延伸50s;30个循环;72℃后延伸7min;4℃终止反应。检测结果如图3。Bar gene PCR reaction program: pre-denaturation at 95°C for 5 min; denaturation at 95°C for 30s; annealing at 56°C for 30s; extension at 72°C for 50s; 30 cycles; extension at 72°C for 7 min; termination at 4°C. The test results are shown in Figure 3.
PCR反应体系:PCR reaction system:
2)Bar基因高表达植株的检测2) Detection of plants with high expression of Bar gene
利用Bar试纸条对PCR检测目的基因呈阳性的植株,按照Bar基因检测试剂盒说明检测Bar基因的表达量。将Bar基因试纸条呈阳性的结果稀释10倍后,再用Bar试纸条复检。保留结果仍为阳性的植株。检测结果见图4。Use Bar test strips to detect the plants that are positive for the target gene by PCR, and detect the expression level of Bar gene according to the instructions of the Bar gene detection kit. After diluting the positive result of the Bar gene test strip by 10 times, recheck with the Bar test strip. Plants that were still positive were retained. The test results are shown in Figure 4.
3)抗原fHbp蛋白的表达3) Expression of antigenic fHbp protein
称取0.1g种荚用PBS缓冲液(137mM NaCl,2.7mM KCl,10mM Na2HPO4,2mM KH2PO4(pH7.4),加水定容至1L)提取总蛋白,料液比为1:3.提取温度4℃,10000rpm,离心20min。上清即为电泳总蛋白样品。Weigh 0.1 g of seed pods and extract total protein with PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 (pH 7.4), add water to volume to 1 L), and the solid-liquid ratio is 1 : 3. The extraction temperature was 4°C, 10000rpm, and centrifugation for 20min. The supernatant is the electrophoresis total protein sample.
12%分离胶的配方(5mL):Recipe for 12% separating gel (5mL):
5%浓缩胶的配方(2mL):Recipe for 5% Stacking Gel (2mL):
按照上述配方制备分离胶和浓缩胶,蛋白与loading buffer5:1混合,沸水浴10min,取10μL进行蛋白fHbp的SDS-PAGE检测。结果见图5。Prepare the separating gel and stacking gel according to the above recipe, mix the protein with loading buffer 5:1, take a boiling water bath for 10 min, and take 10 μL for SDS-PAGE detection of protein fHbp. The results are shown in Figure 5.
4)转化植株Southern-Blot的检测4) Detection of Southern-Blot of transformed plants
取1g样品放入合适的离心管中,在液氮中研碎。加入5mL的CTAB提取缓冲液(75mM1M Tris-HCl(pH8.0),100mM 0.5M EDTA(pH8.0),1.05M NaCl,0.75%40K PVP,加水定容至1L),65℃孵育45min,期间混匀2-3次。从水浴中取出放置室温,13000rpm离心10min,转移上清至一新离心管中。加入等体积氯仿,颠倒混匀2-3min。13000rpm离心10min。重复上述操作至上清无色。加入2倍体积无水乙醇沉淀DNA。13000rpm离心5-7min。弃去上清,干燥沉淀。加入100μL ddH2O回溶沉淀。选择合适的限制性内切酶消化提取的植物DNA。酶切体系:Take 1 g of sample into a suitable centrifuge tube and triturate in liquid nitrogen. Add 5mL of CTAB extraction buffer (75mM 1M Tris-HCl (pH8.0), 100mM 0.5M EDTA (pH8.0), 1.05M NaCl, 0.75% 40K PVP, add water to volume to 1L), incubate at 65°C for 45min, during Mix well 2-3 times. Take out from the water bath and place at room temperature, centrifuge at 13,000 rpm for 10 min, and transfer the supernatant to a new centrifuge tube. Add an equal volume of chloroform, invert and mix for 2-3 min. Centrifuge at 13000rpm for 10min. Repeat the above operation until the supernatant is colorless. Add 2 volumes of absolute ethanol to precipitate DNA. Centrifuge at 13000rpm for 5-7min. The supernatant was discarded and the pellet was dried. Add 100 μL of ddH 2 O to redissolve the pellet. Select appropriate restriction enzymes to digest the extracted plant DNA. Enzyme cleavage system:
酶切结束后,颠倒混匀,加入1/10体积的3M NaAc(pH5.2)和2倍体积无水乙醇,颠倒混匀。13000rpm离心2min,弃去上清,干燥沉淀DNA。加入40μL ddH2O回溶沉淀。阳性对照为pCAMBIA1301-fHbp,阴性对照为非转化的拟南芥DNA。50V电压,在0.8%琼脂糖凝胶中分离DNA。按照Southern-Blot试剂盒检测。结果见图6。After enzyme digestion, invert and mix, add 1/10 volume of 3M NaAc (pH 5.2) and 2 times volume of absolute ethanol, and invert and mix. Centrifuge at 13,000 rpm for 2 min, discard the supernatant, and dry the precipitated DNA. Add 40 μL of ddH 2 O to redissolve the pellet. The positive control was pCAMBIA1301-fHbp, and the negative control was non-transformed Arabidopsis DNA. DNA was separated in a 0.8% agarose gel at 50V. Detected according to Southern-Blot kit. The results are shown in Figure 6.
实施例5 fHbp的分离纯化及含量测定Example 5 Separation, purification and content determination of fHbp
1)拟南芥种荚总蛋白的提取1) Extraction of total protein from Arabidopsis seed pods
将种子置于研钵中,加液氮研磨成粉末,加入1倍体积的PBS提取液,震荡匀浆,置于冰上静置30min,每隔5min颠倒混匀。将混合物置于离心机中10000g4℃离心40min。抽出上清液,重复离心一次。吸取上清。依照上面的方法检测OD595值,计算总蛋白的浓度。The seeds were placed in a mortar, ground into powder with liquid nitrogen, added with 1 volume of PBS extract, shaken to homogenize, placed on ice for 30 min, and mixed by inversion every 5 min. The mixture was centrifuged at 10,000 g at 4°C for 40 min in a centrifuge. Aspirate the supernatant and repeat the centrifugation once. Aspirate the supernatant. The OD 595 value was measured according to the method above, and the concentration of total protein was calculated.
2)fHbp的Ni-NTA纯化2) Ni-NTA purification of fHbp
将提取的植物总蛋白通过0.22μm滤膜过滤。每次取10mL植物总蛋白灌于用Binding Buffer(300mM NaCl,50mMNaH2PO4,10mM咪唑,10mM Tris base,pH8.0)平衡好的Ni-NTA亲和层析柱上。利用蠕动泵使流出液的流速控制在1mL·min-1,收集流出液。用WashBuffer(20mmol·L-1NaH2P04,500mmol·L-1NaCl,pH7.4,20mmol·L咪唑)冲洗大约5个柱体积后,再用Elution Buffer(20mmol·L-1NaH2P04,500mmol·L-1NaCl,pH 7.4,100mmol·L(咪唑)将fHbp从柱子上洗脱下来。结果见图7。The extracted total plant protein was filtered through a 0.22 μm filter. 10 mL of total plant protein was taken each time and poured onto a Ni-NTA affinity chromatography column equilibrated with Binding Buffer (300 mM NaCl, 50 mM NaH 2 PO 4 , 10 mM imidazole, 10 mM Tris base, pH 8.0). The flow rate of the effluent was controlled at 1 mL·min -1 by a peristaltic pump, and the effluent was collected. Wash with WashBuffer (20mmol·L -1 NaH 2 P0 4 , 500mmol·L -1 NaCl, pH7.4, 20mmol·L imidazole) for about 5 column volumes, and then use Elution Buffer (20mmol·L -1 NaH 2 P0 4 , 500 mmol·L -1 NaCl, pH 7.4, 100 mmol·L (imidazole) eluted fHbp from the column. The results are shown in Figure 7.
3)纯化的fHbp浓度的测定3) Determination of purified fHbp concentration
取蛋白标准品(BSA 5mg·mL-1)10μL加PBS稀释至100μL,即浓度为0.5mg·mL-1。将稀释的标准品按0,2,4,6,8,12,16,20μL分别加到96孔板中,加PBS将所有标准品补至20μL。加纯化后的蛋白到96孔板中。各孔加入200μL Bradford染色液,用移液器轻轻吸打混匀,室温放置3-5min,用酶标仪测定A595处的吸光值。根据标准曲线算出蛋白浓度,蛋白浓度约为3.437mg·mL-1。Take 10 μL of protein standard (
实施例6 fHbp亚基疫苗的免疫活性的鉴定Example 6 Identification of the immunological activity of fHbp subunit vaccines
1)免疫制剂的制备1) Preparation of immune preparations
取纯化后fHbp蛋白,加PBS调整其浓度为1.000μg·μL-1,1:1弗氏完全佐剂和弗氏不完全佐剂制成乳化剂,备用。Take the purified fHbp protein, add PBS to adjust its concentration to 1.000 μg·μL -1 , and prepare an emulsifier with 1:1 Freund's complete adjuvant and incomplete Freund's adjuvant for later use.
2)动物免疫试验2) Animal immunity test
将20只6周龄的雌性BALB/C小鼠随机分为2组,即实验组和对照组(每组10只),分别通过腹腔在0,15,30天注射制备好的免疫制剂,初次免疫注射为fHbp/弗氏完全佐剂,加强免疫注射为fHbp/弗氏不完全佐剂,实验组每只注射0.3mL(含fHbp蛋白为20μg),对照组每只注射等量的PBS溶液。Twenty 6-week-old female BALB/C mice were randomly divided into 2 groups, namely the experimental group and the control group (10 mice in each group), and the prepared immune preparations were injected by intraperitoneal injection at 0, 15, and 30 days, respectively. The immunization injection was fHbp/Freund's complete adjuvant, and the booster immunization injection was fHbp/Freund's incomplete adjuvant. Each animal in the experimental group was injected with 0.3 mL (containing 20 μg of fHbp protein), and each animal in the control group was injected with the same amount of PBS solution.
3)动物血清的取得3) Obtaining animal serum
在免疫前,和在初次免疫后10天,加强免疫后25天和40天对小鼠进行断尾取血,并分离血清,-80℃冷冻保存。Before immunization, and 10 days after primary immunization, 25 days and 40 days after booster immunization, mice were tail-docked and bled, and serum was separated and stored frozen at -80°C.
4)fHbp抗血清的ELISA检测4) ELISA detection of fHbp antiserum
用纯化的fHbp,调整浓度使其为20μg·mL-1包被96孔酶标板。洗板3次。用含3%BSA的PBST封闭2hr,除净封闭液。加入在10,25,40天取得的血清,设置阴性对照,即非转化的拟南芥种子总蛋白,37℃反应2hr,洗板3次。加入封闭液5000倍稀释的辣根过氧化物酶(HRP)标记的羊抗鼠IgG,除净抗体溶液。加入100μL底物邻苯二胺(OPD)在暗处显色。每孔加入50μL 2M硫酸终止反应。用酶标仪在492nm处样品的吸光值。血清样品的吸光值是阴性对照的2倍以上判定为阳性结果。抗体滴度以获得阳性结果最高稀释倍数的倒数表示,10只小鼠血清样本A492吸光值的平均数表示该时间抗体的滴度,结果如图8所示。A 96-well microtiter plate was coated with purified fHbp at a concentration of 20 μg·mL -1 . Wash the
5)MenB(菌号29315)毒株悬液的制备5) Preparation of MenB (strain number 29315) strain suspension
在巧克力固体培养基上接种MenB,37℃,5%CO2,培养36-48hr。挑取单菌落。在巧克力液体培养基上培养至OD600为0.5,收集菌体,用PBS缓冲液重悬菌体至终浓度为5x103cfu·mL-1。MenB was inoculated on chocolate solid medium, 37°C, 5% CO 2 , and cultured for 36-48 hr. Pick a single colony. The cells were cultured on chocolate liquid medium to an OD 600 of 0.5, and the cells were collected and resuspended in PBS buffer to a final concentration of 5× 10 3 cfu·mL -1 .
6)fHbp对MenB(菌号29315)毒株的免疫效应保护6) Immune effect protection of fHbp on MenB (strain number 29315) strain
另取腹腔免疫fHbp和PBS 40天后的小鼠共20只(10只实验组,10只对照组),注射100μL的菌液,72hr后观察小鼠的病死情况。并利用下式来计算免疫保护率(RPS):RPS=100x(1-免疫组小鼠死亡百分比)/(对照组小鼠死亡百分比)。由此得出重组fHbp亚基疫苗对MenB免疫保护率为80%,故fHbp能保护小鼠抵御MenB的侵染。A total of 20 mice (10 experimental groups, 10 control groups) after 40 days of intraperitoneal immunization with fHbp and PBS were selected, injected with 100 μL of bacterial solution, and the mortality of the mice was observed 72 hours later. The following formula was used to calculate the immune protection rate (RPS): RPS=100×(1-death percentage of mice in immunization group)/(death percentage of mice in control group). Therefore, the recombinant fHbp subunit vaccine can protect mice against MenB infection by 80%.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principle and spirit of the invention Variations, the scope of the invention is defined by the appended claims and their equivalents.
序列表sequence listing
<110> 温州大学<110> Wenzhou University
<120> 一种脑膜炎球菌fHbp蛋白的表达系统<120> An expression system of meningococcal fHbp protein
<160> 5<160> 5
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 1717<211> 1717
<212> DNA<212> DNA
<213> 启动子(β-phaseolin)<213> Promoter (β-phaseolin)
<400> 1<400> 1
attcgggcag tgattgtata cgactcacta tagggcgaat tgggccctct agatgcatgc 60attcgggcag tgattgtata cgactcacta tagggcgaat tgggccctct agatgcatgc 60
tcgagcggcc gccagtgtga tggatatctg cagaattgcc cttgaaatta tcacgcttcc 120tcgagcggcc gccagtgtga tggatatctg cagaattgcc cttgaaatta tcacgcttcc 120
gcacacgata tccctacaaa tttattattt gttaaacgtt ttcaaaccgc ataaaatttt 180gcacacgata tccctacaaa ttattattattt gttaaacgtt ttcaaaccgc ataaaatttt 180
gtgaagtccc gtctatcttt aatgtagtct aacattttca tattgaaata tataatttac 240gtgaagtccc gtctatcttt aatgtagtct aacattttca tattgaaata tataatttac 240
ttaattttag cgttggtaga aagcataatg atttattctt attcttcttc atataaatgt 300ttaattttag cgttggtaga aagcataatg atttattctt attcttcttc atataaatgt 300
ttaatataca atataaacaa attctttacc ttaagaagga tttcccattt tatattttaa 360ttaatataca atataaacaa attctttacc ttaagaagga tttcccattt tatattttaa 360
aaatatattt atcaaatatt tttcaaccac gtaaatctca taataataag ttgtttcaaa 420aaatatattt atcaaatatt tttcaaccac gtaaatctca taataataag ttgtttcaaa 420
agtaataaaa tttaactcca taattttttt attcgactga tcttaaagca acacccagtg 480agtaataaaa tttaactcca taatttttttt attcgactga tcttaaagca acacccagtg 480
acacaactag ccattttttt ctttgaataa aaaaatccaa ttatcattgt atttttttta 540acacaactag ccatttttttt ctttgaataa aaaaatccaa ttatcattgt attttttttta 540
tacaatgaaa atttcaccaa acaatgattt gtggtatttc tgaagcaagt catgttatgc 600tacaatgaaa atttcaccaa acaatgattt gtggtatttc tgaagcaagt catgttatgc 600
aaaattctat aattcccatt tgacactacg gaagtaactg aagatctgct tttacatgcg 660aaaattctat aattcccatt tgacactacg gaagtaactg aagatctgct tttacatgcg 660
agacacatct tctaaagtaa ttttaataat agttactata ttcaagattt catatatcaa 720agacacatct tctaaagtaa ttttaataat agttactata ttcaagattt catatatcaa 720
atactcaata ttacttctaa aaaattaatt agatataatt aaaatattac ttttttaatt 780atactcaata ttacttctaa aaaattaatt agatataatt aaaatattac ttttttaatt 780
ttaagtttaa ttgttgaatt tgtgactatt gatttattat tctactatgt ttaaattgtt 840ttaagtttaa ttgttgaatt tgtgactatt gatttattat tctactatgt ttaaattgtt 840
ttatagatag tttaaagtaa atataagtaa tgtagtagag tgttagagtg ttaccctaaa 900ttatagatag tttaaagtaa atataagtaa tgtagtagag tgttagagtg ttaccctaaa 900
ccataaacta taagatttat ggtggactaa ttttcatata tttcttattg cttttacctt 960ccataaacta taagatttat ggtggactaa ttttcatata tttcttattg cttttacctt 960
ttcttggtat gtaagtccgt aactagaatt actgtgggtt gccatgacac tctgtggtct 1020ttcttggtat gtaagtccgt aactagaatt actgtgggtt gccatgacac tctgtggtct 1020
tttggttcat gcatggatgc ttgcgcaaga aaaagacaaa gaacaaagaa aaaagacaaa 1080tttggttcat gcatggatgc ttgcgcaaga aaaagacaaa gaacaaagaa aaaagacaaa 1080
acagagagac aaaacgcaat cacacaacca actcaaatta gtcactggct gatcaagatc 1140acagagagac aaaacgcaat cacacaacca actcaaatta gtcactggct gatcaagatc 1140
gccgcgtcca tgtatgtcta aatgccatgc aaagcaacac gtgcttaaca tgcactttaa 1200gccgcgtcca tgtatgtcta aatgccatgc aaagcaacac gtgcttaaca tgcactttaa 1200
atggctcacc catctcaacc cacacacaaa cacattgcct ttttcttcat catcaccaca 1260atggctcacc catctcaacc cacacacaaa cacattgcct ttttcttcat catcaccaca 1260
accacctgta tatattcatt ctcttccgcc acctcaattt cttcacttca acacacgtca 1320accacctgta tatattcatt ctcttccgcc acctcaattt cttcacttca acacacgtca 1320
acctgattat gcgtgtcatc ccatgcccaa atctccatgc atgttccaac caccttctct 1380acctgattat gcgtgtcatc ccatgcccaa atctccatgc atgttccaac caccttctct 1380
cttatataat acctataaat acctctaata tcactcactt ctttcatcat ccatccatcc 1440cttatataat acctataaat acctctaata tcactcactt ctttcatcat ccatccatcc 1440
agagtactac tactctacta ctataatacc ccaacccaac tcatattcaa tactactcta 1500agagtactac tactctacta ctataatacc ccaacccaac tcatattcaa tactactcta 1500
ctccatggcg gatacagcta gaggaaccca tcacgatatc atcggcagag accagtaccc 1560ctccatggcg gatacagcta gaggaaccca tcacgatatc atcggcagag accagtaccc 1560
gatgatgggc cgagaccgag accagtacca gatgtccgga cgaggatctg actactccaa 1620gatgatgggc cgagaccgag accagtacca gatgtccgga cgaggatctg actactccaa 1620
gtctaggcag attgctaaag aagggcaatt ccagcacact ggcggccgtt actagtggat 1680gtctaggcag attgctaaag aagggcaatt ccagcacact ggcggccgtt actagtggat 1680
ccgagctcgg taccaagctg gcgtaatcat gtccaag 1717ccgagctcgg taccaagctg gcgtaatcat gtccaag 1717
<210> 2<210> 2
<211> 29<211> 29
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 2<400> 2
atcgtccatg ggacatcatc atcatcatc 29atcgtccatg ggacatcatc atcatcatc 29
<210> 3<210> 3
<211> 28<211> 28
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 3<400> 3
aagcttaatt agccatagaa atagcagc 28aagcttaatt agccatagaa atagcagc 28
<210> 4<210> 4
<211> 23<211> 23
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 4<400> 4
tcaaatctcg gtgacgggca gga 23tcaaatctcg gtgacgggca gga 23
<210> 5<210> 5
<211> 23<211> 23
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 5<400> 5
atgagcccag aacgacgccc ggc 23atgagcccag aacgacgccc ggc 23
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811425674.0A CN109485704B (en) | 2018-11-27 | 2018-11-27 | Expression system of meningococcal fHbp protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811425674.0A CN109485704B (en) | 2018-11-27 | 2018-11-27 | Expression system of meningococcal fHbp protein |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109485704A CN109485704A (en) | 2019-03-19 |
CN109485704B true CN109485704B (en) | 2022-04-19 |
Family
ID=65697761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811425674.0A Expired - Fee Related CN109485704B (en) | 2018-11-27 | 2018-11-27 | Expression system of meningococcal fHbp protein |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109485704B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009038889A1 (en) * | 2007-08-02 | 2009-03-26 | Children's Hospital And Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CN101914567A (en) * | 2010-07-16 | 2010-12-15 | 中国农业科学院生物技术研究所 | A method for expressing and identifying exogenous genes in fungi |
CN102028941A (en) * | 2011-02-11 | 2011-04-27 | 中国医学科学院医学生物学研究所 | Neisseria meningitidis group B recombinant protein chimeric vaccine and preparation method thereof |
CN102356089A (en) * | 2008-02-21 | 2012-02-15 | 诺华有限公司 | Meningococcal fhbp polypeptides |
WO2012032498A2 (en) * | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
CN102724988A (en) * | 2009-09-30 | 2012-10-10 | 诺华有限公司 | Expression of meningococcal fHBP polypeptides |
CN102776226A (en) * | 2012-07-23 | 2012-11-14 | 吉林农业大学 | Method for producing cecropins by using alfalfa as bioreactor |
CN103320466A (en) * | 2013-07-10 | 2013-09-25 | 吉林农业大学 | A kind of vegetable oil body skin care lotion containing vascular endothelial growth factor active polypeptide |
CN103981191A (en) * | 2014-04-10 | 2014-08-13 | 吉林农业大学 | Plant seed expression system for single-chain antibody against CD20 |
CN104114706A (en) * | 2012-02-02 | 2014-10-22 | 诺华股份有限公司 | Promoters for increased protein expression in meningococcus |
CN104774867A (en) * | 2015-01-26 | 2015-07-15 | 长春格鲁斯特生物科技有限公司 | Method for producing chicken beta antibacterial peptide Gal-3 by using alfalfa as bioreactor |
-
2018
- 2018-11-27 CN CN201811425674.0A patent/CN109485704B/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009038889A1 (en) * | 2007-08-02 | 2009-03-26 | Children's Hospital And Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CN102356089A (en) * | 2008-02-21 | 2012-02-15 | 诺华有限公司 | Meningococcal fhbp polypeptides |
CN102724988A (en) * | 2009-09-30 | 2012-10-10 | 诺华有限公司 | Expression of meningococcal fHBP polypeptides |
CN101914567A (en) * | 2010-07-16 | 2010-12-15 | 中国农业科学院生物技术研究所 | A method for expressing and identifying exogenous genes in fungi |
WO2012032498A2 (en) * | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
CN102028941A (en) * | 2011-02-11 | 2011-04-27 | 中国医学科学院医学生物学研究所 | Neisseria meningitidis group B recombinant protein chimeric vaccine and preparation method thereof |
CN104114706A (en) * | 2012-02-02 | 2014-10-22 | 诺华股份有限公司 | Promoters for increased protein expression in meningococcus |
CN102776226A (en) * | 2012-07-23 | 2012-11-14 | 吉林农业大学 | Method for producing cecropins by using alfalfa as bioreactor |
CN103320466A (en) * | 2013-07-10 | 2013-09-25 | 吉林农业大学 | A kind of vegetable oil body skin care lotion containing vascular endothelial growth factor active polypeptide |
CN103981191A (en) * | 2014-04-10 | 2014-08-13 | 吉林农业大学 | Plant seed expression system for single-chain antibody against CD20 |
CN104774867A (en) * | 2015-01-26 | 2015-07-15 | 长春格鲁斯特生物科技有限公司 | Method for producing chicken beta antibacterial peptide Gal-3 by using alfalfa as bioreactor |
Non-Patent Citations (4)
Title |
---|
Over-expression of fHbp in Arabdopsis for development of meningococcal serogroup B subunit vaccine;Nuo Xu等;《Biotechnology Journal》;20160427;第11卷(第7期);973-980 * |
Phaseolus vulgaris beta-type phaseolin storage protein gene, complete cds;GenBank: J01263.1;《GenBank》;19980617;1-2 * |
亚基疫苗fHbp在大肠杆菌和拟南芥中的表达及免疫学研究;许诺;《中国博士学位论文全文数据库 医药卫生科技辑》;中国学术期刊(光盘版)电子杂志社;20160815(第08期);E059-42 * |
重组B群脑膜炎球菌fHBP融合蛋白的表达和免疫原性研究;彭世泽等;《中国生物工程杂志》;20101231;第31卷(第5期);28-33 * |
Also Published As
Publication number | Publication date |
---|---|
CN109485704A (en) | 2019-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in Chlamydomonas reinhardtii chloroplast | |
Amani et al. | Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157: H7 in mice | |
US8846052B2 (en) | Bacterial toxin vaccine | |
AU4317289A (en) | Oral immunization by transgenic plants | |
EP1481061B1 (en) | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses | |
JPH04500152A (en) | Potyvirus coat protein gene and plants transformed with it | |
Shulga et al. | Expression and characterization of hepatitis B surface antigen in transgenic potato plants | |
CN109485704B (en) | Expression system of meningococcal fHbp protein | |
AU2007229381A1 (en) | Compositions and Methods for the Improvement of Plants | |
He et al. | Stable expression of foot-and-mouth disease virus protein VP1 fused with cholera toxin B subunit in the potato (Solanum tuberosum) | |
US6329568B1 (en) | Tospovirus resistance in plants | |
CN102732531B (en) | A rice blast resistance gene RMg7 or RMg8 or RMg9 and its application | |
EP0429497B1 (en) | Cocumber mosaic virus coat protein gene | |
CN108342400B (en) | Genetic engineering bacterium for recombinant expression of oxalate oxidase and construction method and application thereof | |
CN112301044B (en) | A kind of polyclonal antibody of NbAPX3 gene of Bunsen cigarette and its preparation method and application | |
CA2443264A1 (en) | Gene encoding plant protein tm2a, conferring resistance to tomato mosaic virus | |
US8591915B2 (en) | Plant-derived vaccines against respiratory syncytial virus | |
EP1235920A2 (en) | Down-regulation and silencing of allergen genes in transgenic peanut seeds | |
KR102726134B1 (en) | Vaccinia virus recombinant A27L protein and kit for diagnosing orthopoxvirus antibody comprising the same | |
Ma et al. | Preparation of polyclonal antibodies of rubisco large and small subunits and their application in the functional analysis of the genes | |
CN117003886A (en) | An oral vaccine prepared from transgenic lettuce expressing O157:H27 antigen | |
Ma et al. | Potential large scale production of meningococcal vaccines by stable overexpression of fHbp in the rice seeds | |
KR101783677B1 (en) | Method for mass producing dengue virus vaccine using plant viral expression system | |
CN106591356B (en) | Method for expressing salmon calcitonin and special expression cassette thereof | |
WO2013152624A1 (en) | Synthetic glyphosate-resistant gene and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220419 |
|
CF01 | Termination of patent right due to non-payment of annual fee |